TBPH

NASDAQ Healthcare

Theravance Biopharma, Inc. - Ordinary Shares

Biotechnology

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

�� 市场数据

价格	$17.23
成交量	407,265
市值	887.22M
贝塔系数	0.170
RSI（14日）	81.3 超买
200日均线	$15.68
50日均线	$16.52
52周最高	$21.03
52周最低	$8.33
市盈率	8.36
Forward P/E	12.72
Price / Book	2.97